Figure 3.
Figure 3. PFS and OS in patients treated with daratumumab plus pom-dex. At a median follow-up of 13.1 months, the median PFS (A) and median OS (B) are shown.

PFS and OS in patients treated with daratumumab plus pom-dex. At a median follow-up of 13.1 months, the median PFS (A) and median OS (B) are shown.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal